DRD2 activation inhibits choroidal neovascularization in patients with Parkinson’s disease and age-related macular degeneration
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci174199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Thibaud Mathis und 20 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France. Hauptthemen laut MEDLINE: Choroidal Neovascularization, Levodopa, Macular Degeneration, Parkinson Disease. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ANR, LABEX LIFESENSES, IHU FOReSIGHT.
Abstract (Originalsprache)
Neovascular age-related macular degeneration (nAMD) remains a major cause of visual impairment and puts considerable burden on patients and health care systems. l-DOPA–treated Parkinson’s disease (PD) patients have been shown to be partially protected from nAMD, but the mechanism remains unknown. Using murine models that combine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine–induced (MPTP-induced) PD and laser-induced nAMD with standard PD treatment of l-DOPA/DOPA-decarboxylase inhibitor or specific dopamine receptor inhibitors, we here demonstrate that l-DOPA treatment–induced increase of dopamine-mediated dopamine receptor D2 (DRD2) signaling inhibits choroidal neovascularization independently of MPTP-associated nigrostriatal pathway lesion. Analyzing a retrospective cohort of more than 200,000 patients with nAMD receiving anti-VEGF treatment from the French nationwide insurance database, we show that DRD2 agonist–treated PD patients have a significantly delayed age of onset of nAMD and reduced need for anti-VEGF therapies, similar to the effects of the l-DOPA treatment. While providing a mechanistic explanation for an intriguing epidemiological observation, our findings suggest that systemic DRD2 agonists might constitute an adjuvant therapy to delay and reduce the need for anti-VEGF therapy in patients with nAMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France.
- Hopital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
- UMR-CNRS 5510, MATEIS, Institut National des Sciences Appliquées, Université Lyon 1, Campus de la Doua, Villeurbanne, France.
- Service d'ophtalmologie, CHU Dijon, Dijon, France.
- Ramsaysanté, Clinique d'Argonay, Argonay, France.
- Service de Biostatistiques et D'Information Médicale (DIM), CHU Dijon Bourgogne, INSERM, Université de Bourgogne, CIC 1432, Module Épidémiologie Clinique, Dijon, France.
Förderung
- ANR
- LABEX LIFESENSES
- IHU FOReSIGHT
Zitieren
APA
Mathis, T., Baudin, F., Mariet, A. S., Augustin, S., Bricout, M., Przegralek, L., Roubeix, C., Benzenine, É., Blot, G., Nous, C., Kodjikian, L., Mauget-Faÿsse, M., Sahel, J. A., Plevin, R., Zeitz, C., Delarasse, C., Guillonneau, X., Creuzot-Garcher, C., Quantin, C., …, & Sennlaub, F. (2024). DRD2 activation inhibits choroidal neovascularization in patients with Parkinson’s disease and age-related macular degeneration. Journal of Clinical Investigation. https://doi.org/10.1172/jci174199
Vancouver
Mathis T, Baudin F, Mariet AS, Augustin S, Bricout M, Przegralek L, et al. DRD2 activation inhibits choroidal neovascularization in patients with Parkinson’s disease and age-related macular degeneration. Journal of Clinical Investigation. 2024. doi:10.1172/jci174199
BibTeX
@article{Mathis2024,
author = {Mathis, Thibaud and Baudin, Florian and Mariet, Anne-Sophie and Augustin, Sébastien and Bricout, Marion and Przegralek, Lauriane and Roubeix, Christophe and Benzenine, Éric and Blot, Guillaume and Nous, Caroline and Kodjikian, Laurent and Mauget-Faÿsse, Martine and Sahel, José-Alain and Plevin, Robin and Zeitz, Christina and Delarasse, Cécile and Guillonneau, Xavier and Creuzot-Garcher, Catherine and Quantin, Catherine and Hunot, Stéphane and Sennlaub, Florian},
title = {DRD2 activation inhibits choroidal neovascularization in patients with Parkinson’s disease and age-related macular degeneration},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci174199}
}
EUVIMED